Percutaneous trans-hepatic bilateral biliary stenting in Bismuth IV malignant obstruction

Table 1 Patients’ baseline demographics

Patients (n)	35
Female	18/35 (51.4)
Age (yr), mean ± SD	69 ± 13
Tumor type
Cholangiocarcinoma	10/35 (28.5)
Hepatocellular carcinoma	9/35 (25.7)
Pancreatic carcinoma	5/35 (14.3)
Gastric cancer	2/35 (5.7)
Bile duct cancer	2/35 (5.7)
Colorectal cancer	2/35 (5.7)
Gallbladder carcinoma	2/35 (5.7)
Lung cancer	1/35 (2.8)
Breast cancer	1/35 (2.8)
Non-Hodgkin lymphoma	1/35 (2.8)

Table 2 Procedural details and outcomes

Stents used (n)	48
Stent deployment
Y-configuration	18/35 (51.4%)
T-configuration	17/35 (48.6%)
Technical success	35/35 (100%)
Clinical success	27/35 (77.1%)
Decreased bilirubin levels	27/33 (81.8%)
Serum bilirubin decrease	60.5% (23%-92%)
Survival interval (d), mean (range)	168 (0-1763)
6-mo survival rate	47.10%
Primary patency (d), mean (range)	105 ( 0-719)
Secondary patency (d), mean (range)	181 (100-1763)
Peri-procedural death	2/35 (5.7%)
Major complications	2/35 (5.7%)
Minor complications	6/35 (17.1%)
Hospitalization time (d), mean ± SD	10.2 ± 3.9